Active Ingredient History
Formoterol, also known as eformoterol, is a long-acting β2 agonist (LABA) used as a bronchodilator in the management of asthma and chronic obstructive pulmonary disease (COPD). Formoterol has an extended duration of action compared to short-acting β2 agonists such as salbutamol (albuterol), which are effective for 4 h to 6 h. Formoterol has a relatively rapid onset of action compared to other LABAs, and is effective within 2-3 minutes. The 2022 Global Initiative for Asthma report recommends a combination formoterol/inhaled corticosteroid inhaler as both a preventer and reliever treatment for asthma in adults. In children, a short-actingβ2 agonist is still recommended. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Airway Management (Phase 4)
Airway Obstruction (Phase 2)
Alzheimer Disease (Phase 2)
Asthma ()
Asthma, Exercise-Induced (Phase 4)
Bronchiectasis (Phase 4)
Bronchiolitis Obliterans (Phase 2)
Bronchitis (Phase 3)
Bronchitis, Chronic (Phase 4)
Cachexia (Phase 2)
Cognitive Dysfunction (Phase 2)
COVID-19 (Phase 3)
Emphysema ()
Eosinophils (Phase 2/Phase 3)
Exercise (Phase 4)
Healthy Volunteers (Phase 1)
Heart Septal Defects, Ventricular (Phase 4)
Hematopoietic Stem Cell Transplantation (Phase 2)
Hypersensitivity (Phase 2/Phase 3)
Hypoxia (Phase 3)
Idiopathic Pulmonary Fibrosis (Phase 2)
Inflammation (Phase 4)
Lung Diseases (Phase 4)
Lung Diseases, Obstructive (Phase 2/Phase 3)
Lung Neoplasms (Phase 1)
Medication Adherence (Phase 4)
Pneumonia (Phase 3)
Precancerous Conditions (Phase 1)
Pulmonary Emphysema (Phase 4)
Quality of Life (Phase 4)
Respiratory Distress Syndrome (Phase 2)
Sleep Disorders, Intrinsic (Phase 3)
Smoking (Phase 3)
Status Asthmaticus (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue